Abstract
Progressive renal fibrosis in chronic kidney disease (CKD) greatly contributes to end-stage renal failure and is associated with high mortality. The identification of renal fibrosis biomarkers for the diagnosis and the monitoring of disease progression in CKD is urgently needed. Whole-transcriptomic analysis of renal tissues in a unilateral ureteral obstruction (UUO) mouse model revealed that the mRNA level of Bcl-3, an atypical member of the IκB family, was induced 6.3-fold 2 days after UUO. Compared with renal tissues in sham-operated mice, increases in Bcl-3 mRNA and protein in the renal tissues in the UUO model were accompanied with increases in other markers of renal fibrosis, including human epididymis protein 4 (HE4), a recently identified biomarker of renal fibrosis. Immunohistochemical analysis revealed that both Bcl-3 and HE4 were located in the plasma of renal tubule cells. Serum protein levels of Bcl-3 and HE4 rose with the development of renal fibrosis in UUO mouse model. We found that the serum protein levels of both HE4 and Bcl-3 were elevated in CKD patients compared with healthy controls. Moreover, a significant positive correlation between Bcl-3 and HE4 (r = 0.939, p < 0.0001) was observed in CKD patients. These data suggest that Bcl-3 can serve as a novel valuable biomarker of renal fibrosis in CKD.
Introduction: The Need for Non-Invasive Biomarkers
Chronic Kidney Disease (CKD) is a global health crisis that often leads to end-stage renal failure. The common denominator in this progression is renal fibrosis—a self-perpetuating "scarring" process where healthy tissue is replaced by extracellular matrix proteins like collagen. Currently, the "gold standard" for assessing fibrosis is a renal biopsy. However, biopsies are invasive, carry risks like hemorrhage, and cannot be performed frequently to monitor a patient's status. While some serum biomarkers like HE4 exist, they lack specificity. There is an urgent need for specific, sensitive, and non-invasive biomarkers to catch fibrosis early and track it accurately.
Methods and Bioinformatics Screening
The researchers employed a multi-stage approach starting with bioinformatics. They re-analyzed public transcriptomic data (GEO accession GSE79443) from a mouse model of kidney injury to identify genes in the NFκB signaling pathway that were significantly upregulated during the early stages of fibrosis.
Following the initial screen, the Unilateral Ureteral Obstruction (UUO) mouse model was used to induce progressive renal fibrosis. Molecular validation was performed using RT-PCR to measure mRNA levels and Western Blotting for protein levels in both kidney tissue and serum across a 15-day timeline. Histological techniques, including H&E and Sirius red staining, visualized tissue damage and collagen deposition. Finally, the findings were validated in a clinical cohort of 31 CKD patients and 25 healthy controls.
Results: Bcl-3 as a "First Responder" to Kidney Injury
The UUO model successfully induced significant renal fibrosis. Ligated kidneys (L) showed marked atrophy and increased collagen deposition compared to non-ligated (NL) controls. Molecular analysis confirmed that Bcl-3 mRNA levels spiked 6.3-fold just two days after injury.
Crucially, Bcl-3 levels began to rise earlier than HE4, suggesting it could be a "first responder" biomarker. Immunohistochemistry revealed that both Bcl-3 and HE4 are primarily located in the cytoplasm of renal tubule cells, providing a clear biological source for the proteins found in the serum.
In human CKD patients, serum Bcl-3 levels showed a significant positive correlation with HE4 (r = 0.939, p < 0.0001). Furthermore, higher serum Bcl-3 levels were associated with lower eGFR and higher levels of creatinine and urea nitrogen. In diagnostic performance tests, Bcl-3 outperformed HE4, with an Area Under the Curve (AUC) of 0.7440 compared to 0.6556 for HE4.
Discussion and Future Directions
Bcl-3 is an atypical member of the IκB family. Previous research indicates that Bcl-3 stabilizes Smad3, a key player in the TGFβ signaling pathway that drives fibrosis. This suggests that Bcl-3 is not just a marker but a functional participant in the fibrotic process.
While promising, several hurdles remain for clinical implementation. The human validation cohort was relatively small, and a high-throughput, clinical-grade ELISA for Bcl-3 needs to be developed. Future work must also address the specificity of Bcl-3, as it can be elevated in certain cancers. Understanding the exact release mechanism of Bcl-3 into the bloodstream—whether via exosomes or cell death—could further refine its use as an early diagnostic tool.
Summary updated